

RAJJU SHROFF ROFEL UNIVERSITY, VAPI

| Program             | Master of Pharmacy (M.Pharm) | Semester - 1 |
|---------------------|------------------------------|--------------|
| Type of Course      | -                            |              |
| Prerequisite        |                              |              |
| Course Objective    | -                            |              |
| Effective From A.Y. | 2023-24                      |              |

| Teaching Scheme (Contact Hours) |          |            |                       | Examination Scheme    |                       |                       |       |       |
|---------------------------------|----------|------------|-----------------------|-----------------------|-----------------------|-----------------------|-------|-------|
|                                 |          | Lab Credit |                       | Theory Marks          |                       | Practical Marks       |       | Total |
| Lecture                         | Tutorial |            | External<br>Marks (T) | Internal<br>Marks (T) | External<br>Marks (P) | Internal<br>Marks (P) | Marks |       |
| 4                               | -        | -          | 4                     | 75                    | 25                    | -                     | -     | 100   |

SEE - Semester End Examination, CIA - Continuous Internal Assessment (It consists of Assignments/Seminars/Presentations/MCQ Tests, etc.)

| ~     | rse Content   | T - Teaching Hours   W  |        |                |
|-------|---|---|--------|----------------|
| Sr.   | Topics  |   | T      | W              |
| 1     | Sustained Rele  | ase (SR) and Controlled Release (CR) formulations   | 10     | 17             |
|       | advantages/ di<br>formulation, Me<br>classification, p<br>Pharmacogene  | basic concepts,<br>sadvantages, factors influencing, Physicochemical & biological approaches for SR/CR<br>echanism of Drug Delivery from SR/CR formulation. Polymers: introduction, definition,<br>properties and application Dosage Forms for Personalized Medicine: Introduction, Definition,<br>tics, Categories of Patients for Personalized Medicines: Customized drug delivery systems,<br>Medicines, 3D printing of pharmaceuticals, Telepharmacy.   |        |                |
| 2     | Rate Controlled   | d Drug Delivery Systems   | 10     | 17             |
|       | Delivery Systen   | ndamentals, Types, Activation; Modulated Drug<br>ns; Mechanically activated, pH activated, Enzyme activated, and Osmotic activated Drug<br>ns Feedback regulated Drug Delivery Systems; Principles & Fundamentals   |        |                |
| _     |   |   | 40     |                |
| 3     | Gastro-Retenti  | ve Drug Delivery Systems  | 10     | 17             |
| 3     | Principle, conco<br>of GI transit tim   | <b>ve Drug Delivery Systems</b><br>epts advantages and disadvantages, Modulation<br>ne approaches to extend GI transit. Buccal Drug Delivery Systems: Principle of mucoadhesion,<br>d disadvantages, Mechanism of drug permeation, Methods of formulation and its   | 10     | 17             |
| 3     | Principle, conce<br>of GI transit tim<br>advantages and<br>evaluations.   | epts advantages and disadvantages, Modulation<br>ne approaches to extend GI transit. Buccal Drug Delivery Systems: Principle of mucoadhesion,   | 6      |                |
| _     | Principle, conce<br>of GI transit tim<br>advantages and<br>evaluations.<br>Occular Drug D   | epts advantages and disadvantages, Modulation<br>ne approaches to extend GI transit. Buccal Drug Delivery Systems: Principle of mucoadhesion,<br>d disadvantages, Mechanism of drug permeation, Methods of formulation and its  |        |                |
| _     | Principle, conce<br>of GI transit tim<br>advantages and<br>evaluations.<br>Occular Drug D<br>Barriers of dru  | epts advantages and disadvantages, Modulation<br>ne approaches to extend GI transit. Buccal Drug Delivery Systems: Principle of mucoadhesion,<br>d disadvantages, Mechanism of drug permeation, Methods of formulation and its<br>relivery Systems  |        | 10             |
| 4     | Principle, conce<br>of GI transit tim<br>advantages and<br>evaluations.<br>Occular Drug D<br>Barriers of dru<br>Transdermal D<br>Structure of ski   | epts advantages and disadvantages, Modulation<br>ne approaches to extend GI transit. Buccal Drug Delivery Systems: Principle of mucoadhesion,<br>d disadvantages, Mechanism of drug permeation, Methods of formulation and its<br>relivery Systems<br>g permeation, Methods to overcome barriers.   | 6      | 17<br>10<br>17 |
| 4     | Principle, conce<br>of GI transit tim<br>advantages and<br>evaluations.<br>Occular Drug D<br>Barriers of dru<br>Transdermal D<br>Structure of ski   | epts advantages and disadvantages, Modulation<br>ne approaches to extend GI transit. Buccal Drug Delivery Systems: Principle of mucoadhesion,<br>d disadvantages, Mechanism of drug permeation, Methods of formulation and its<br>relivery Systems<br>g permeation, Methods to overcome barriers.<br>rug Delivery Systems<br>in and barriers, Penetration enhancers, Transdermal<br>ystems, Formulation and evaluation.   | 6      | 10             |
| 4     | Principle, conce<br>of GI transit tim<br>advantages and<br>evaluations.<br>Occular Drug D<br>Barriers of dru<br>Transdermal D<br>Structure of ski<br>Drug Delivery S<br>Protein and Pe  | epts advantages and disadvantages, Modulation<br>ne approaches to extend GI transit. Buccal Drug Delivery Systems: Principle of mucoadhesion,<br>d disadvantages, Mechanism of drug permeation, Methods of formulation and its<br>relivery Systems<br>g permeation, Methods to overcome barriers.<br>rug Delivery Systems<br>in and barriers, Penetration enhancers, Transdermal<br>ystems, Formulation and evaluation.   | 6      | 10<br>17       |
| 4     | Principle, conce<br>of GI transit tim<br>advantages and<br>evaluations.<br>Occular Drug D<br>Barriers of dru<br>Transdermal D<br>Structure of ski<br>Drug Delivery S<br>Protein and Pe  | epts advantages and disadvantages, Modulation<br>ne approaches to extend GI transit. Buccal Drug Delivery Systems: Principle of mucoadhesion,<br>d disadvantages, Mechanism of drug permeation, Methods of formulation and its<br>relivery Systems<br>g permeation, Methods to overcome barriers.<br>rug Delivery Systems<br>in and barriers, Penetration enhancers, Transdermal<br>ystems, Formulation and evaluation.<br>ptide Delivery<br>tein delivery. Formulation and Evaluation of delivery systems of proteins and other macromolecules | 6      | 17             |
| 4 5 6 | Principle, conce<br>of GI transit tim<br>advantages and<br>evaluations.<br>Occular Drug D<br>Barriers of dru<br>Transdermal D<br>Structure of ski<br>Drug Delivery S<br>Protein and Pe<br>Barriers for pro<br>Vaccine deliver | epts advantages and disadvantages, Modulation<br>ne approaches to extend GI transit. Buccal Drug Delivery Systems: Principle of mucoadhesion,<br>d disadvantages, Mechanism of drug permeation, Methods of formulation and its<br>relivery Systems<br>g permeation, Methods to overcome barriers.<br>rug Delivery Systems<br>in and barriers, Penetration enhancers, Transdermal<br>ystems, Formulation and evaluation.<br>ptide Delivery<br>tein delivery. Formulation and Evaluation of delivery systems of proteins and other macromolecules | 6 10 7 | 10<br>17<br>11 |

| Suggested Distri |             |               |             |         |          |
|------------------|-------------|---------------|-------------|---------|----------|
| Level            | Remembrance | Understanding | Application | Analyze | Evaluate |
| Weightage        | 80          | 15            | 5           | 0       | 0        |

NOTE : This specification table shall be treated as a general guideline for the students and the teachers. The actual distribution of marks in the question paper may vary slightly from above table.



## RAJJU SHROFF ROFEL UNIVERSITY, VAPI

## **Course Outcomes**

| At the | At the end of this course, students will be able to: |  |  |  |  |
|--------|--|--|--|--|--|
| C01    | To know an   | d understand the concept of sustained, controlled and customized drug delivery |  |  |  |
| C02    | To know an   | d understand the concept of various novel drug delivery systems                |  |  |  |

## **Reference Books**

| 1.  | CONTROLLED & NOVEL DRUG DELIVERY (TextBook)<br>By N.K. JAIN   CBS PUBLISHERS, Pub. Year 1997   |
|-----|--|
| 2.  | NOVEL DRUG DELIVERY SYSTEM (TextBook)<br>By D.T BAVISKAR, D.K. JAIN   CBS PUBLISHERS, Pub. Year 2012   |
| 3.  | BIOPHARMACEUTICS & PHARMACOKINETICS: A TREATISE (TextBook)<br>By D.M. BRAHMANKAR, S.B. JAISWAL   VALLABH PRAKASHAN, Pub. Year 2009                               |
| 4.  | PROGRESS IN CONTROLLED & NOVEL DRUG DELIVERY SYSTEM (TextBook)<br>By N.K. JAIN   CBS PUBLISHERS, Pub. Year 2001  |
| 5.  | PERSONALIZED MEDICINE: MOTIVATION, CHALLENGES, PROGRESS<br>By LAURA H, GOETZ MD, NICHOLAS J   FERTILITY & STERILITY JOURNAL, Pub. Year 2018                      |
| 6.  | TELEPHARMACY: A PHARMACISTS PERSPECTIVE ON THE CLINICAL BENEFITS & CHALLENGES<br>By NISSEN LM, POWEL A   INTEGRATED PHARMACY-RESEARCH & PRACTICE, Pub. Year 2016 |
| 7.  | NOVEL DRUG DELIVERY SYSTEM<br>By Y.W. CHEIN   MARCEL & DEKKER, Pub. Year 2005  |
| 8.  | ISRN PHARMACEUTICS ARTICLE 528079<br>By KERALIYA RAJESH, Pub. Year 2012  |
| 9.  | <b>Encyclopedia of controlled delivery</b><br>By Edith Mathiowitz   Wiley Interscience Publication, John Wiley and Sons, Inc, New York! Chichester/Weinheim      |
| 10. | Controlled Drug Delivery Systems<br>By Robinson, J. R., Lee V. H. L   Marcel Dekker,Inc., New York, Pub. Year 1992   |